CliffBio
small molecule

NORVIR

RITONAVIR

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameNORVIR
Active ingredientRITONAVIR
Strength100MG/PACKET
Dosage formPOWDER
RouteORAL
ModalitySmall molecule
FDA approvalJune 2017
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NORVIR patent cliff — loss of exclusivity — | CliffBio